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Previous studies suggest that reduced leukocyte telomere length (LTL) is related to higher risk of 
mortality and several chronic conditions, including coronary heart disease (CHD) and stroke. However, 
the consistency of this association differs across populations. We investigated the relationship of LTL 
with CHD, stroke and all-cause mortality together with non-fatal CHD and stroke events in a Russian 
cohort with a mean age of 58 years at baseline. Data from 1,144 individuals in the Russian subset of 
the Health Alcohol and Psychosocial Factors in Eastern Europe (HAPIEE) cohort study were used. 
The associations between LTL at baseline and fatal/non-fatal outcomes during 12 years of follow-up 
were assessed using multivariable Cox regression models, which yielded adjusted hazard ratios (HR). 
Compared to individuals in the shortest tertile, those in the longest tertile of LTL had a 42% lower risk 
of death from all-causes (HR 0.58; 95% CI: 0.39–0.88) and 58% lower risk of death from CHD (HR 0.42; 
95%CI: 0.19–0.97). Similar patterns of association were identified for non-fatal and combined fatal/
non-fatal CHD and stroke events but the associations were weaker. Consistent with results of previous 
studies in Western populations, this cohort of elderly Russian adults found an inverse association 
between LTL and CHD and all-cause mortality. These findings reinforce the hypothesis that LTL may 
play (or be a marker of) an aetiological role in human health across diverse populations.
Telomeres are repetitive DNA sequences located at the ends of each chromosome. Telomeres become shorter after 
every cell division and as such their length is considered to be a marker of biological ageing1,2. Consistent with 
this hypothesis, reduced leukocyte telomere length (LTL) and a higher rate of its attrition have been reported to 
associate with various chronic diseases, including cardiovascular disease (CVD), diabetes, cancer or Alzheimer`s 
disease3–6.
Most previous studies have reported inverse associations between LTL and mortality7–10. One of the largest 
was carried out on nearly 65,000 individuals on a Danish general population sample, which found a 40% dif-
ference in the risk of death between participants in the shortest and longest telomere length deciles8. However, 
the available evidence is not entirely consistent, with several studies reporting null findings, particularly those 
which examine older individuals above the age of 70 years11,12. Two recent studies from the US also found that 
the association of LTL with mortality differed by ethnicity9,13. Although their findings were conflicting, with one 
suggesting stronger and the other weaker association between LTL and cardiovascular mortality among African 
Americans compared to White Europeans, this observation emphasises the importance to explore the association 
of LTL with disease endpoints in diverse populations.
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CVD is the leading cause of mortality worldwide, with coronary heart disease (CHD) and stroke estimated to 
be responsible for more than 15 million deaths in 201514. Although age-standardised mortality rates due to CVD 
has been decreasing in most global regions, the absolute number of deaths from vascular causes has increased 
globally. In many Eastern European states, particularly in Russia, CVD mortality increased sharply in the mid-
1990s, and even today, more people die of CVD than from all other causes combined15.
To date, studies of the relationship between LTL and mortality or CHD/stroke risk have been conducted in 
North America, Western Europe or Asian populations; so far there has been no such study in Eastern Europe. 
In this report, we investigated the association of LTL with all-cause, CHD and stroke mortality, as well as with 
non-fatal CHD/stroke events, in a Russian population sample using data from a prospective cohort study with 12 
years of follow-up.
Methods
Study population and analytical sample. We conducted a prospective analysis using data from the 
Russian subset of the Health Alcohol and Psychosocial Factors in Eastern Europe (HAPIEE) cohort study. At 
baseline, the study recruited men and women aged 45–70 years in two districts of the city of Novosibirsk16. From 
the original 9360 participants (response rate 61%), 1144 individuals were randomly selected at baseline for the 
purpose of more intensive phenotyping. LTL was measured in this subsample.
All participants provided informed consent and study protocols were approved by ethical committees at 
University College London and Novosibirsk State Medical University. The study was conducted in accordance 
with the relevant ethical guidelines and regulations.
Data collection. Baseline data collection of the HAPIEE study took place between 2003 and 2005. 
Participants filled in a comprehensive questionnaire and provided information on their socio-economic cir-
cumstances, lifestyle habits and health. They also underwent medical examination and provided venous blood 
samples.
Genomic DNA was isolated from the randomly selected 1144 blood samples by phenol-chloroform extrac-
tion, and stored at minus 70°C until further laboratory analysis. Telomere length analysis was performed using 
quantitative real-time PCR-based method17,18. As previously described19, quantitative reactions were conducted 
separately for telomeres and the hemoglobin gene in pairs of 96-well plates in corresponding wells. Each plate 
housed a series of DNA dilutions (0.5, 1, 2, 5, 10, 20, and 30 ng) which were utilized for the construction of a 
standard curve and quantitation of each sample. Each reaction was done with 10 ng of DNA. The composition of 
the reaction mixture for telomere analysis included 270 nM tel1b primer (5′-CGGTTT(GTTTGG)5GTT-3′), 900 
nM tel2b primer (5′-GGCTTG(CCTTAC)5CCT-3′), 0.2X SYBR Green I, 5 mM dithiothreitol, 1% dimethylsul-
foxide, 0.2 mM each dNTP, 1.5 mM MgCl2, and 1.25 U of DNA polymerase. The reaction volume was 15 μL. The 
PCR program was conducted as follows: a predenaturation step for 10 min at 95°C followed by 25 cycles: dena-
turation at 95°C for 15 s, annealing at 54°C for 30 s, and elongation at 72°C for 90 s. The reaction mixture for the 
β hemoglobin gene contained 300 nm Hbg1 primer (5′-GCTTCTGACACAACTGTGTTCACTAGC-3′), Hgb2 
primer (5′-CACCAACTTCATCCACGTTCACC-3′), 0.2X SYBR Green I, 5 mM dithiothreitol, 1% dimethylsul-
foxide, 0.2 mM each dNTP, 1.5 mM MgCl2, and 1.25 U of DNA polymerase. The PCR program began with a 
predenaturation step for 3 min at 95°C followed by 25 cycles: 95°C for 15 s, 58°C for 20 s, and 72°C for 20 s. 
Both reactions were carried out in a StepOnePlus™ Real-Time PCR System (Applied Biosystems, Thermo Fisher 
Scientific Inc., USA). Calculations were performed with the standard cycler software. Single-copy gene (T:S) ratio 
were done to obtain the relative LTL. If the standard deviation in three replications exceeded 0.5, the sample was 
rejected. Each plate housed three control samples with normal LTL and one with short. Relative signal intensities 
from control samples were tested to ensure the comparability of the plates.
As the applied DNA extraction method can affect the LTL results due to contamination20, the protocol 
included procedures of cleaning from protein and other organic substances. For quality control, we assessed the 
quantity and concentration of DNA using the Microplate Spectrophotometer Epoch (BioTek, USA). To assess the 
contamination by protein or other organic substances, 260/280 nm and 260/230 nm wave length concentration 
indexes were used, respectively. Quality limits of index 260/280>1.8 and index 260/230>2.0 indicated DNA 
which was not acceptable for analysis. Only 1% of the samples was excluded from the analysis due to this crite-
rion. For these cases, DNA extraction was performed from another aliquot if they were available. To ensure the 
stability and consistency of the procedures all samples were analysed with the same DNA extraction method and 
laboratory equipment.
Participants were followed-up for mortality and non-fatal cardiovascular outcomes. Data on all-cause and 
cause-specific mortality were collected at the Research Institute of Internal and Preventive Medicine using a 
number of sources, including the Population Registration Bureau (ZAGS) and the Novosibirsk Office of the State 
Statistical Bureau (Rosstat). Regarding all-cause mortality, the available information was also updated when sub-
jects were invited to participate in subsequent waves of the study, for example by speaking to relatives of deceased 
study participants. For cause-specific mortality, cause of death was available only for CHD and stroke. This is 
because access to death registration data was not available between 2011 and 2015 due to administrative reasons; 
however, CHD [ICD-10: I20-I25] and stroke deaths [ICD-10: I60-I69] could be identified via the myocardial 
infarction (MI) and stroke registers (described below). Non-fatal CHD and stroke events were primarily iden-
tified through the Research Institute of Internal and Preventive Medicine’s registers of MI and stroke, originally 
established in the frame of the WHO MONICA project21, using medical records and hospital discharge reports. 
Non-fatal CHD and stroke events were additionally confirmed and identified by self-report in subsequent waves 
of data collection. The mean follow-up time for mortality and non-fatal cardiovascular events was 12 years.
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Statistical analysis. The associations between LTL and fatal/non-fatal end-points were assessed using Cox 
regression analysis. LTL was analysed as both a categorical and continuous variable. The categorical variable was 
derived as the tertiles of LTL; the group with the shortest LTL was used as the reference category. When LTL was 
used as a continuous variable, the hazard ratio of mortality or CVD events was modelled per one standard devi-
ation (SD) higher LTL (in our dataset, 1 SD was equal to 0.41 kbp). Proportionality assumptions were tested with 
Schoenfeld residuals.
We examined the associations in two multivariable adjusted models. In model 1, hazard ratios were adjusted 
for age and sex as these are the two most common confounders. In model 2, hazard ratios were further adjusted 
for those socio-demographic, lifestyle and metabolic factors which are often associated with both LTL and mor-
tality outcomes22,23. These were: smoking (never; ex-; regular smokers), alcohol intake (abstainers; moderate 
drinkers – intake less than 15 g/day for females or 30 g/day for males; heavy drinkers – intake more than 15 g/day 
for females or 30 g/day for males), education attainment (primary or less; vocational; secondary; higher degree), 
marital status (living with or without partner), body mass index, systolic blood pressure, serum cholesterol con-
centration and self-reported history of prior CVD.
All statistical analysis was carried out with the statistical software Stata 13.1 (StataCorp, TX, USA).
Results
Table 1 shows the distribution of covariates across LTL tertiles at baseline. Individuals with longer LTL were younger 
and they were more likely to be women and non-smokers. Other than age and sex, none of the other baseline cardi-
ovascular risk factors showed particularly convincing associations with LTL. Distribution of covariates across LTL 
tertiles were mostly similar to the pooled results when men and women were examined separately, however, the 
inverse association with blood pressure was observed only in females (Supplementary Tables S1 and S2).
During 12 years of follow-up, 149 participants died, including 58 due to CHD or stroke and 89 due to 
non-vascular causes. Composite fatal and non-fatal CHD and stroke end points included 182 events (124 non-fatal). 
Individuals in the longest LTL tertile had a lower risk of death from any cause as compared to those in the shortest 
LTL tertile (HR 0.57, 95%CI 0.38–0.85; P=0.003 for trend across the three tertile groups), and the association was 
similar when LTL was modelled as continuous variable (HR 0.81, 95%CI 0.68–0.97 per 1-SD longer LTL; P=0.021) 
(Table 2). Similarly, longer LTL was associated with lower risk of death from CHD (HR 0.44, 95% CI 0.20–0.99 
comparing longest to shortest LTL tertile; P=0.043 for trend across the three tertiles), with the equivalent estimate 
for death from CHD being HR 0.72 (95%CI: 0.52–1.00; P=0.047 per 1-SD longer LTL). Combining CHD and 
stroke deaths together, the estimates were directionally consistent, but the 95%CI were wider (Table 2). Regarding 
non-cardiovascular deaths, the association was not linear, as the lowest risk was observed in the middle tertile of 
LTL. This pattern, which also had an impact on the linearity of the association with all-cause mortality, may reflect 
the heterogeneous nature of this outcome (which includes, for example, cancer and external causes of deaths). All 
examined associations remained robust to multivariable adjustment (model 2 in Table 2).
The association of the combined fatal and non-fatal CHD and stroke events with LTL is shown in Table 3. In 
keeping with the associations with vascular mortality, the point estimates of the effect estimates were consistent 
with a potential underlying inverse relationship between LTL and fatal/nonfatal CHD and stroke; however, the 
associations were weak and the 95%CI included the null. For example, the per-SD longer LTL association with 
fatal/nonfatal CHD was HR 0.83 (95%CI: 0.69–1.00; P=0.051). When non-fatal outcomes were examined sepa-
rately, the strength of most associations was found to be even weaker (Supplementary Table S3).
Covariates
Leucocyte telomere length tertiles
p-valuea
Shortest LTL Middle LTL Longest LTL







Age in years (mean, SD) 58.4 (6.9) 57.9 (6.8) 56.2 (6.8) <0.001
Females (%) 44.0 58.8 57.7 <0.001
Current smokers (%) 30.9 21.3 23.4 0.006
Heavy drinkers (%) 11.0 7.6 9.2 0.235
Married (%) 79.1 73.0 75.9 0.144
University education (%) 34.8 27.8 36.5 0.101
Systolic blood pressure (mean, SD) 140.7 (23.2) 141.9 (24.9) 137.8 (23.1) 0.050
Body mass index (mean, SD) 28.1 (4.7) 28.4 (5.1) 28.4 (5.3) 0.575
Total cholesterol cc. (mean, SD) 6.4 (1.2) 6.5 (1.3) 6.4 (1.1) 0.544
Self-reported history of prior CVD (%) 21.2 21.0 19.2 0.743
Table 1. Distribution of covariates across leucocyte telomere length tertiles at baseline in the Russian arm of 
the HAPIEE study. SD – standard deviation; LTL – leukocyte telomere length; CVD – cardiovascular disease. 
aANOVA or Chi-square test.
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Discussion
In this prospective analysis of Russian adults, we found longer LTL to be associated with a lower risk of fatal CHD 
and all-cause mortality. We identified directionally consistent inverse relationships of LTL with risk of combined 
fatal/non-fatal CHD and stroke outcomes, however these associations was weaker and largely driven by fatal 
outcomes.
This is the first study to explore the relationship of LTL and risk of cause-specific mortality in an Eastern 
European prospective cohort. Our findings are consistent with previous reports and highlight the role that LTL 
may play in disease risk. Our findings, that subjects who have longer LTL have a 56% lower risk of fatal CHD is 
in keeping with a meta-analysis of 24 studies including 8,400 cases of CHD, of which 248 were fatal, and which 
identified a 48% lower risk of fatal CHD for a similar comparison3. Similar to this previously reported study, the 
relationships we report were robust to inclusion of conventional cardiovascular risk factors.
The exact mechanisms linking telomere length with mortality or chronic diseases are not entirely clear, and a 
number of potential plausible explanations exist. Some authors suggest the possibility of a direct effect, potentially 
through the role of cellular senescence in atherosclerosis24. Indeed, a Mendelian randomization study suggests 
that LTL may be causal risk factor for CHD25, however such studies need to be interpreted with caution, especially 
when genetic variants may be affected by pleiotropy26. In contrast to being causally implicated, it is also possible 
that LTL represents a marker of cardiovascular ageing because unhealthy lifestyle (e.g. smoking, alcohol, poor 
diet) and the consequent oxidative stress affect both LTL and the risk of CVD independently27. A recent review 
provides several reasons for a cautionary interpretation of whether LTL represents a causal risk factor for ageing28. 
For example, it is argued that the inverse association of LTL with mortality attenuates with advancing age29. While 
it may be difficult to compare estimates between studies (given the opportunity for ecological confounding30), 
our study, with a mean age of ~60 and followed up for 12 years, provides new evidence that in East European 
populations, LTL does associate with death in older age. We stress, however, that our findings are observational in 
nature, and cannot be used to deduce cause and effect.
Our findings has strengths including studying an under-represented population, a prospective study design, 
and cause-specific mortality from Russian registries. Our study also has limitations including a rather small sample 
size and potential for misclassification of the non-fatal outcomes (which is the most likely reason for the weaker 
Cause of death n death model
Leucocyte telomere length tertiles Per 1 SD increase in telomere 
lengthShortest LTL Middle LTL Longest LTL p-value 
for trendHR HR (95% CI) HR (95% CI) HR (95%CI) p-value
Any cause 149
model 1 1.00 (ref) 0.61 (0.41–0.90) 0.57 (0.38–0.85) 0.003 0.81 (0.68–0.97) 0.021
model 2 1.00 (ref) 0.57 (0.38–0.84) 0.58 (0.39–0.88) 0.004 0.82 (0.69–0.98) 0.030
CHD (ICD-10: I20-I25) 46
model 1 1.00 (ref) 0.75 (0.38–1.45) 0.44 (0.20–0.99) 0.043 0.72 (0.52–1.00) 0.047
model 2 1.00 (ref) 0.68 (0.34–1.33) 0.42 (0.19–0.97) 0.035 0.72 (0.51–1.00) 0.050
CHD or Stroke (ICD-10: 
I20-I25 or I60-I69) 58
model 1 1.00 (ref) 0.98 (0.55–1.75) 0.57 (0.28–1.15) 0.141 0.79 (0.60–1.05) 0.108
model 2 1.00 (ref) 0.89 (0.49–1.61) 0.56 (0.27–1.15) 0.128 0.80 (0.60–1.07) 0.129
Non-CVD causes (ICD-10 
codes other than I00-I99) 89
model 1 1.00 (ref) 0.44 (0.25–0.76) 0.58 (0.35–0.96) 0.016 0.85 (0.68–1.06) 0.156
model 2 1.00 (ref) 0.41 (0.24–0.71) 0.62 (0.37–1.03) 0.025 0.86 (0.69–1.08) 0.202
Table 2. Relationship between leucocyte telomere length tertiles and mortality outcomes in the Russian arm of 
the HAPIEE study. LTL – leukocyte telomere length; HR – hazard ratio; CI – confidence interval; SD – standard 
deviation; CHD – coronary heart disease; ICD-10–10th revision of the International Classification of Diseases. 
model 1: adjusted for age and sex. model 2: adjusted for age, sex, smoking, alcohol, education, marital status, 
body mass index, systolic blood pressure, total cholesterol cc. and self-reported history of prior CVD.
Cardiovascular 
outcome (fatal or 
non-fatal) n event model
Leucocyte telomere length tertiles
Per 1 SD increase in telomere 
length
Shortest 
LTL Middle LTL Longest LTL p-value 
for trendHR HR (95% CI) HR (95% CI) HR (95%CI) p-value
CHD 134
model 1 1.00 (ref) 0.80 (0.53–1.20) 0.75 (0.49–1.14) 0.168 0.83 (0.69–1.00) 0.051
model 2 1.00 (ref) 0.73 (0.48–1.09) 0.77 (0.51–1.18) 0.203 0.85 (0.70–1.02) 0.077
Stroke 56
model 1 1.00 (ref) 0.75 (0.40–1.41) 0.77 (0.40–1.46) 0.397 0.88 (0.67–1.18) 0.400
model 2 1.00 (ref) 0.71 (0.38–1.34) 0.74 (0.39–1.43) 0.349 0.88 (0.66–1.17) 0.368
CHD or stroke 182
model 1 1.00 (ref) 0.83 (0.58–1.17) 0.81 (0.56–1.16) 0.228 0.87 (0.75–1.02) 0.087
model 2 1.00 (ref) 0.75 (0.53–1.07) 0.81 (0.56–1.16) 0.217 0.88 (0.75–1.03) 0.100
Table 3. Relationship between leucocyte telomere length tertiles and combined fatal or non-fatal CHD and 
stroke events in Russian arm of the HAPIEE study. LTL – leukocyte telomere length; HR – hazard ratio; CI – 
confidence interval; SD – standard deviation; CHD – coronary heart disease. model 1: adjusted for age and 
sex. model 2: adjusted for age, sex, smoking, alcohol, education, marital status, body mass index, systolic blood 
pressure, total cholesterol cc. and self-reported history of prior CVD.
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associations with LTL observed for non-fatal disease). Our inability to separate out non-vascular disease into specific 
causes means we are unable to tease out why the relationship of LTL with non-vascular death appeared U-shaped – 
this likely reflects differing effects on discrete causes of death, and accounts for a similar plateauing of the association 
of all-cause mortality comparing those with intermediate and long LTL to those with short LTL.
In conclusion, our study identifies longer LTL to be associated with substantial reductions in risk of CHD and 
all-cause mortality in a prospective cohort of elderly Russians. This highlights the need for further investigations 
to elucidate the mechanism by with LTL may impact human health.
Data Availability
Availability of data from the HAPIEE study is restricted due to legal reasons. Further information and access can be 
requested by contacting the principle investigator, Professor Martin Bobak (m.bobak@ucl.ac.uk) who will seek approv-
al by the HAPIEE Study Steering Committee and the Research Ethics Committee at UCL and participating centres.
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